EUVIMEDEUVIMED entdecken
StudienprotokollOpen Access · CC BY 4.0

Study Protocol of a Prospective Phase 2 Study of Chlorophyllin for the Management of Brain Radionecrosis in Patients With Diffuse Glioma ( CHROME )

Archya Dasgupta iD, Saranga Sawant, Abhishek Chatterjee, Vikram Gota, Arpita Sahu iD, Amitkumar Choudhari, Kajari Bhattacharya, Ameya Puranik, Indraja Dev, Aliasgar Moiyadi, Prakash Shetty, Vikas Singh und 8 weitere

Cancer Medicine · 2025

DOI: 10.1002/cam4.70657 ↗

Kurz gefasst

Studienprotokoll in der Zeitschrift Cancer Medicine, 2025. Verfasst von Archya Dasgupta und 19 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiation Oncology, Tata Memorial Centre, Mumbai, India. Hauptthemen laut MEDLINE: Brain Neoplasms, Chlorophyllides, Glioma, Radiation Injuries. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Chlorophyllin (CHL) effectively decreases the side effects of radiotherapy (RT) by scavenging radiation‐induced free radicals and reactive oxygen species in preclinical trials. This study aims to assess the efficacy of oral CHL for the treatment of brain radionecrosis in patients with diffuse glioma.

Methods

This is a phase 2 trial prospective, interventional study. Adults (> 18 years) with a histological diagnosis of diffuse glioma developing radionecrosis will be eligible for the study. Radionecrosis will be identified using standard imaging protocols with magnetic resonance imaging (MRI) with or without positron emission tomography (PET). Patients will be accrued in two strata: symptomatic (stratum A) and asymptomatic (stratum B). Chlorophyllin will be prescribed to all patients using a morning oral dose of 750 mg before breakfast for 3 months. In addition, participants in stratum A will be given a tapering dose of dexamethasone for 1 month, while stratum B will not be receiving any steroids. Imaging with an MRI brain protocol and PET scan will be planned at 1 month and MRI at 3 months after starting CHL. The primary endpoint is the clinical‐radiological response at 1 month. Secondary endpoints include response at 3 months, biological responses, survival analysis, and quality‐of‐life scores. The total sample size is 118 (60 and 58 in stratum A and B, respectively), with one interim analysis planned.

Discussion

Radionecrosis leads to significant morbidity and is usually treated with corticosteroids, which can lead to several side effects from both acute and long‐term use. Refractory radionecrosis requires treatment with bevacizumab or surgical resection. Chlorophyllin is a cheap, safe, and readily available phytopharmaceutical drug, which is being investigated in the phase 2 study and, if proven effective, can be considered an alternative for treating radionecrosis. Trial Registration: Clinical Trial Registry India (CTRI): CTRI/2023/08/056166; ClinicalTrials.gov : NCT06016452

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Brain NeoplasmsChlorophyllidesGliomaRadiation InjuriesAdultAgedFemaleHumansMaleMiddle AgedYoung AdultBrainClinical Trials, Phase II as TopicMagnetic Resonance ImagingNecrosisPositron-Emission TomographyProspective StudiesQuality of Life

Stichwörter der Autor:innen

chlorophyllindiffuse gliomaglioblastomahigh‐grade gliomaradionecrosis

Substanzen

Chlorophyllideschlorophyllin

Autor:innen und Institutionen

  • Department of Radiation Oncology, Tata Memorial Centre, Mumbai, India.
  • Homi Bhabha National Institute (HBNI), Mumbai, India.
  • Clinical Research Secretariat (CRS), Tata Memorial Centre, Mumbai, India.
  • Department of Clinical Pharmacology, The Advanced Centre for Treatment, Research and Education in Cancer, Tata Memorial Centre, Navi Mumbai, India.
  • Department of Radio-Diagnosis, Tata Memorial Centre, Mumbai, India.
  • Department of Nuclear Medicine, Tata Memorial Centre, Mumbai, India.

ORCID-Profile: Archya Dasgupta, Arpita Sahu, Nandini Menon, Tejpal Gupta

Zitieren

APA

Dasgupta, A., Sawant, S., Chatterjee, A., Gota, V., Sahu, A., Choudhari, A., Bhattacharya, K., Puranik, A., Dev, I., Moiyadi, A., Shetty, P., Singh, V., Menon, N., Epari, S., Sahay, A., Shah, A., Bano, N., Shaikh, F., Jirage, A., & Gupta, T. (2025). Study Protocol of a Prospective Phase 2 Study of Chlorophyllin for the Management of Brain Radionecrosis in Patients With Diffuse Glioma ( CHROME ). Cancer Medicine. https://doi.org/10.1002/cam4.70657

Vancouver

Dasgupta A, Sawant S, Chatterjee A, Gota V, Sahu A, Choudhari A, et al. Study Protocol of a Prospective Phase 2 Study of Chlorophyllin for the Management of Brain Radionecrosis in Patients With Diffuse Glioma ( CHROME ). Cancer Medicine. 2025. doi:10.1002/cam4.70657

BibTeX
@article{Dasgupta2025,
  author = {Dasgupta, Archya and Sawant, Saranga and Chatterjee, Abhishek and Gota, Vikram and Sahu, Arpita and Choudhari, Amitkumar and Bhattacharya, Kajari and Puranik, Ameya and Dev, Indraja and Moiyadi, Aliasgar and Shetty, Prakash and Singh, Vikas and Menon, Nandini and Epari, Sridhar and Sahay, Ayushi and Shah, Aekta and Bano, Nazia and Shaikh, Farnaz and Jirage, Aabha and Gupta, Tejpal},
  title = {Study Protocol of a Prospective Phase 2 Study of Chlorophyllin for the Management of Brain Radionecrosis in Patients With Diffuse Glioma ( CHROME )},
  journal = {Cancer Medicine},
  year = {2025},
  doi = {10.1002/cam4.70657}
}
Kostenlos starten →